Pulmotil G100 Premix for medicated feedingstuff

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Aktīvā sastāvdaļa:

Tilmicosin phosphate

Pieejams no:

Elanco GmbH

ATĶ kods:

QJ01FA91

SNN (starptautisko nepatentēto nosaukumu):

Tilmicosin phosphate

Deva:

100 gram(s)/kilogram(s)

Zāļu forma:

Premix for medicated feeding stuff

Receptes veids:

POM: Prescription Only Medicine as defined in relevant national legislation

Ārstniecības joma:

tilmicosin

Autorizācija statuss:

Authorised

Autorizācija datums:

1997-01-24

Produkta apraksts

Health Products Regulatory Authority
24 July 2018
CRN000YKH
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Pulmotil G100 Premix for medicated feedingstuff
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Tilmicosin (as phosphate)
100 g/kg
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Premix for medicated feedingstuff. A yellowish tan to reddish tan free
flowing
granular material.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs and rabbits
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Pigs: Prevention and treatment of respiratory disease caused by
_Actinobacillus _
_pleuropneumoniae, Mycoplasma hyopneumoniae, Pasteurella multocida
_and other
organisms sensitive to tilmicosin.
Rabbits: Prevention and treatment of respiratory disease caused by
_Pasteurella _
_multocida _and_ Bordetella bronchiseptica, _susceptible to
tilmicosin.
4.3 CONTRAINDICATIONS
Horses or other E_quidae_, must not be allowed access to feeds
containing tilmicosin.
Horses fed with tilmicosin medicated feeds may present signs of
toxicity with
lethargy, anorexia, reduction of feed consumption, loose stools,
colic, distension of
the abdomen and death.
Do not use in case of hypersensitivity to tilmicosin or to any of the
excipients.
Health Products Regulatory Authority
24 July 2018
CRN000YKH
Page 2 of 7
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Under practical conditions, the management of respiratory disease
outbreaks
recognises that acutely ill animals are inappetant and require
parenteral therapy.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Inappropriate use of the product may increase the prevalence of
bacteria resistant to
tilmicosin and may decrease the effectiveness of treatment with
tilmicosin related
substances.
Official, national and regional antimicrobial policies should be taken
into account
when the product is used.
Due to the likely variability (time, geographical) in the occurrence
of the resistance of
bacteria for tilmi